The role and mechanisms of lipofuscin formation in macular degeneration
The role and mechanisms of lipofuscin formation in macular degeneration
批准号:
8417703
负责人:
ILYAS WASHINGTON
金额:
$38.24万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-02-01 至 2016-01-31
关键词:
AffectAgeAgingAnabolismAnimal ModelAnimalsBlindnessCarbohydratesCell DeathCell physiologyCellsClinicalCytoplasmic GranulesDepositionDeuteriumDevelopmentDiseaseDrug KineticsDrusenElderlyElectroretinographyEyeFunctional disorderFundusGarbageGoalsGrantHalf-LifeHealthHistologyHumanHydrogenImpairmentIn VitroInflammatoryInterventionKineticsLabelLeadLinkLipidsLipofuscinMacular degenerationMeasurementMeasuresMetabolismMethodsNamesNanosphereNeurodegenerative DisordersPharmaceutical PreparationsPhysiologicalPigmentsPlayPublic HealthResearchRetinalRetinal DegenerationRodent ModelRoleScientistSpeedSymptomsTestingTimeTissuesTritiumVisionVitamin AWorkclinically relevantcrosslinkdimerin vivolink proteinnovelpreventpublic health relevanceresponsesmall moleculetheoriestoolvisual cycle
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall goal of this research is to better understand the role of ocular lipofuscin in macular degeneration. In doing so we develop clinically relevant ways to inhibit lipofuscin formation (as possible interventions for macular degeneration) and develop animal models of lipofuscin-induced macular degeneration. The specific aims of this application are: AIM 1) elucidate the relationship between lipofuscin and retinal health and the mechanism of lipofuscin formation: a) determine whether slowing lipofuscin biosynthesis can prevent ocular aging and vision loss in rodent models of macular degeneration; b) determine whether increasing the concentration of vitamin A dimers in the RPE leads to the formation of lipofuscin granules and drusen; and c) determine whether animals models of macular degeneration can be generated by rapidly increasing lipofuscin pigments; and AIM 2) elucidate pharmacokinetics vitamin A and vitamin A dimers in the eye: a) determine the time it takes to swap vitamin A for D3-vitamin A in the outer segments; b) establish the RPE half life of vitamin A dimers; c) determine whether the rate of lipofuscin pigment biosynthesis increases with age or whether lipofuscin pigments themselves "accumulate" with age, and; d) compare visual cycle kinetics of vitamin A vs. D3-vitamin A. We will achieve these specific aims by slowing down or speeding up lipofuscin formation in animals, using novel methods developed in our lab, and correlating eye health to lipofuscin concentration. In evaluating eye health in response to changes in lipofuscin we employ standard methods such as, tissue histology, fundus autofluorescence, electroretinogram measurements, inflammatory status and quantification of vitamin A dimers. For the elucidation of the ocular pharmacokinetics of vitamin A and its dimers we track their fate and/or biosynthesis using deuterium or tritium labeled species. We intend to show that the biosynthesis of vitamin A dimers (also called or lipofuscin pigments or A2E and ATR-dimer) is an early and critical step in the formation of lipofuscin granules (or deposits) in the RPE cell layer of the eye; that lipofuscin granules lead to the formation of drusen (or drusen like material) and ultimately cell death and vision impairment. We intend to show that stopping the biosynthesis of vitamin A dimers is an effective clinical strategy to stopping the formation of lipofuscin and drusen, as a method to stop the progression of the most prevalent forms of macular degeneration. We intend to gather evidence to show that the administration of D3-vitamin A is a safe, practical, method to prevent the progression of several forms of macular degeneration.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A diabetes pill to replace insulin injections
-
批准号:9808104
-
项目类别:
-
资助金额:$74.0万
-
财政年份:2018
-
负责人:ILYAS WASHINGTON
-
依托单位:
A diabetes pill to replace insulin injections
-
批准号:10017963
-
项目类别:
-
资助金额:$75.99万
-
财政年份:2018
-
负责人:ILYAS WASHINGTON
-
依托单位:
Phase 1 Safety and Pharmacokinetics of ALK001 in people over 60
-
批准号:8252282
-
项目类别:
-
资助金额:$16.52万
-
财政年份:2012
-
负责人:ILYAS WASHINGTON
-
依托单位:
The role and mechanisms of lipofuscin formation in macular degeneration
-
批准号:8217066
-
项目类别:
-
资助金额:$40.25万
-
财政年份:2011
-
负责人:ILYAS WASHINGTON
-
依托单位:
The role and mechanisms of lipofuscin formation in macular degeneration
-
批准号:8607956
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2011
-
负责人:ILYAS WASHINGTON
-
依托单位:
The role and mechanisms of lipofuscin formation in macular degeneration
-
批准号:8795185
-
项目类别:
-
资助金额:$39.45万
-
财政年份:2011
-
负责人:ILYAS WASHINGTON
-
依托单位:
The role and mechanisms of lipofuscin formation in macular degeneration
-
批准号:8022372
-
项目类别:
-
资助金额:$34.76万
-
财政年份:2011
-
负责人:ILYAS WASHINGTON
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: